Understand the science before the headlines.
Evidence-led peptide research, emerging metabolic therapeutics, clinical-trial intelligence, Australian regulation and laboratory methods — translated with context, citations and clear limits.
Four ways into the evidence.
Start with a compound, follow a clinical programme, understand the regulatory environment, or go deeper into how peptide research is measured and verified.
Peptide Library
Compound profiles, mechanisms, published evidence, limitations and current research status.
02 / TRIALSClinical Trials
Phase, sponsor, endpoints, status, completion dates and result summaries in one place.
03 / AUSTRALIATGA & Regulation
Australian scheduling, approvals, regulatory decisions and plain-English context.
04 / METHODSLab Science
HPLC, LC–MS, peptide identity, purity, stability, synthesis and analytical interpretation.
Start with the questions readers ask most.
Direct routes into current regulatory status, evidence interpretation and laboratory verification—each dated, source-linked and written to separate what is known from what is not.
GLP-1 Medicines in Australia (2026): TGA Approval, PBS Access and Safety Updates
A dated, source-linked guide to GLP-1 medicines in Australia: TGA-approved indications, PBS access, Wegovy’s listing status and 2026 safety updates.
Open the evidence →Mounjaro PBS Australia 2026: Listing Status & Negotiations
Current answer — checked 8 October 2026: Mounjaro (tirzepatide) is TGA-approved in Australia for type 2 diabetes and chronic weight management, but it is…
Open the evidence →TGA Retatrutide Alert: Semaglutide Found in Tested Vial
The TGA says a product sold as retatrutide contained undeclared semaglutide, no retatrutide, and was linked to a serious adverse event. What the 14…
Open the evidence →How to Read a Peptide Certificate of Analysis: A Field-by-Field Guide
An Australia-focused guide to verifying a peptide certificate of analysis, spotting red flags and separating identity, HPLC area, assay, sterility and regulatory status.
Open the evidence →How to Read an HPLC Chromatogram: Peaks, Area & Purity
A practical HPLC chromatogram guide: retention time, peak area, baseline integration, system suitability and why area percent is not mass purity.
Open the evidence →Mass Spectrometry vs HPLC for Peptide Testing
A practical guide to what HPLC, mass spectrometry and LC–MS can—and cannot—prove about peptide identity, purity, assay, impurities and safety claims.
Open the evidence →Compounds people are searching now.
Each profile explains mechanisms, human and preclinical evidence, safety signals, limitations and Australian regulatory context.
GHK-Cu Copper Peptide: Evidence, Human Studies & Australian Status (2026)
GHK-Cu evidence guide: human skin studies, topical-versus-injectable limits, copper-peptide quality claims and current Australian regulatory context.
Retatrutide: Evidence, Phase 3 Trials & Australian Regulatory Status (2026)
Evidence-led overview of retatrutide (LY3437943): mechanism, Phase 2 peer-reviewed data, 2026 Phase 3 topline results, safety signals and…
MOTS-c Australia: Human Evidence, Exercise Studies and WADA Status
Evidence-led MOTS-c guide covering human exercise and biomarker studies, limits of animal research, Australian regulatory context and 2026…
AOD-9604 Australia: Human Trials, TGA Status and WADA Rules
Evidence-led AOD-9604 profile covering human weight-loss trials, Schedule 4 status in Australia, the 2026 WADA prohibition and research…
Tesamorelin: Approved HIV-Lipodystrophy Evidence and Limits of Extrapolation
Tesamorelin is a GHRH analogue with a specific prescription indication in the United States. Its evidence cannot be…
PT-141 Australia: Bremelanotide Evidence, FDA Approval and Safety Limits
Evidence-led review of bremelanotide (PT-141): the narrow FDA indication, Phase 3 trial endpoints, safety warnings, Australian regulatory context…
New from the journal.
Long-form explainers, evidence updates and research notes designed to answer the question behind the search query — not just repeat it.
Weight Regain After Stopping GLP-1 Medicines: What Trials Show
Compare STEP 1, STEP 4 and SURMOUNT-4 withdrawal findings, their study timelines and weight-change denominators, and limits on predicting individual regain.
Read analysis →Semaglutide and Kidney Disease: What the FLOW Trial Shows
FLOW tested semaglutide in 3,533 adults with type 2 diabetes and chronic kidney disease. Read the kidney outcomes, evidence limits and Australian TGA status.
Read analysis →CagriSema Trial Results: What REDEFINE 1 and REDEFINE 2 Actually Show
CagriSema combines cagrilintide and semaglutide. Read the phase 3 REDEFINE 1 and 2 results, analysis methods, safety findings and evidence limits.
Read analysis →MASH and MASLD Drug Evidence: FDA Decisions and Trial Tracker
Track MASH drug evidence across FDA decisions and primary trials, with biopsy endpoints, analysis populations and confirmatory-outcome limits kept separate.
Read analysis →Amylin vs GLP-1: CagriSema and Emerging Obesity Drugs
Understand how amylin and GLP-1 targets differ, what CagriSema combines, and what published cagrilintide, petrelintide and eloralintide trials show.
Read analysis →Oral GLP-1 Medicines: Approval and Clinical-Trial Evidence Tracker
Compare FDA decisions and primary trial evidence for oral semaglutide and orforglipron, with dates, trial identifiers and clear limits on comparisons.
Read analysis →Sales pressure belongs nowhere near scientific interpretation.
Elite Peps Australia operates as a knowledge-only publication. No product sales, checkout incentives or commercial recommendation engine.